Fulcrum Therapeutics Inc. (FULC), a clinical-stage biopharma company developing therapies for rare genetic diseases, has a near-term clinical trial catalyst to watch involving its lead drug candidate Pociredir.
Pociredir, an oral therapeutic, is under a phase Ib study in patients with sickle cell disease, dubbed PIONEER. In the study, the company is currently evaluating the 12 mg dose and 20 mg dose of Pociredir.
For comments and feedback contact: editorial@rttnews.com
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.